問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Taipei Venterans General Hospital Taoyuan Branch

Division of Hematology & Oncology

更新時間:2023-09-19

蕭慈慧
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

137Cases

2023-12-01 - 2028-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-09-01 - 2025-02-14

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-02-01 - 2026-06-22

Phase III

Active
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
  • Condition/Disease

    Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Test Drug

    Amikacin liposome inhalation suspension (ALIS)

Participate Sites
12Sites

Not yet recruiting6Sites

Recruiting2Sites

Terminated4Sites

2023-06-01 - 2025-06-23

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2023-12-01 - 2028-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-08-31 - 2032-02-12

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2018-06-08 - 2021-01-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-08-01 - 2028-02-29

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting1Sites

2024-06-20 - 2027-09-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-06-01 - 2025-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites